Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML

Recently, novel drugs like venetoclax plus 5-azacytidine (VA) were reported to have promising efficacy in refractory acute myeloid leukemia (AML). However, there are still some cases presented with novel drugs resistance, and its genetics composition and clinical phenotype are urging to study. We de...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Biomark Res
Main Authors: Wang, JingHan, Ye, Xingnong, Fan, Cuihua, Zhou, Jie, Luo, Shuna, Jin, Jingxia, Chen, Dan, Zheng, Yan, Wu, Cai, Zhu, Xiaoqiong, Jin, Jie, Huang, Jian
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2020
Fag:
Letter to the Editor
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7687845/
https://ncbi.nlm.nih.gov/pubmed/33292606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00246-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker